Keywords regulatory T cells CTLA-4 prostate cancer neoadjuvant immunotherapy CyTOF single-cell RNA sequencing tumor-associated macrophages dendritic cells Introduction To date, immune checkpoint blockade immunotherapy (ICB) has proven largely ineffective for patients with prostate cancer (PCa).1,2,3 Agents targeting the PD-1/PD-L1 pathway alone or in combination with androgen receptor inhibitors,4,5,6 chemotherapy,7 or PARP inhibition8 have failed in phase III trials.9 Similarly, CTLA-4...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Casey Ager
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial
|
By Casey Ager, Aleksandar Obradovic, Patrick McCann, Matthew G. Chaimowitz, Alexander Wang, Neha Shaikh, Parin N Shah, Samuel S. Pan, Caroline J. Laplaca, Renu K. Virk, Jessica Hill, Collin Jugler, Grace DeFranco, Nilika Bhattacharya, Kade R. Copple, PHUONG DUNG NGUYEN Verified, Phương Nguyên, Howard I. Scher, Guarionex Joel DeCastro, Christopher Anderson, James McKiernan, Catherine S. Spina, Mark Stein, Karie Runcie, Charles Drake, Andrea Califano, Matthew Dallos
|
Cell Reports Medicine
Verified
ArticleVolume 7, Issue 3102638Open access Affiliations & Notes 1Department of Medicine, Division of Hematology and Oncology, Columbia University Irving Medical Center, New York, NY, 10032, United States of America 2Columbia Center for Translational Immunology, Columbia University Irving Medical Center, New York, NY, 10032, United States of America 3Department of Immunology, Mayo Clinic Arizona, Phoenix, AZ, 85054, United States of America 4Department of Urology, Mayo Clinic Arizona, Phoenix,...
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer
Highlights • Protein-inferred activity clustering shows complex immune cells in CSPC metastases • ADT and aPD-1 treatment induces robust infiltrates of CD8+, CD4+ T cells, and Tregs • T cell infiltration determined by scRNA-seq correlated with T cells shown by qmIF • Baseline tumor and immune clusters associated with clinical outcomes Summary When compared to other malignancies, the tumor microenvironment (TME) of primary and castration-resistant prostate cancer (CRPC) is relatively devoid of...
Systematic elucidation and pharmacological targeting of tumor-infiltrating regulatory T cell master regulators
|
By Aleksandar Obradovic, Casey Ager, Mikko Turunen, Thomas R. Nirschl, Mohsen Khosravi-Maharlooei, Alina Iuga, Christopher Jackson, Srinivasan Yegnasubramanian, Lorenzo Tomassoni, Ester Calvo Fernández, Patrick McCann, Meri Rogava, Angelo M DeMarzo, Christina M. Kochel, Mohamad E. Allaf, Trinity J. Bivalacqua, Michael Lim, Ronald Realubit, Charles Karan, Charles G. Drake, Andrea Califano
|
Cell Press
Verified
Keywords tumor immunology regulatory T cells master regulator analysis TRPS1 gemcitabine cancer systems biology Introduction To manifest as clinically apparent disease, cancer must evade a complex repertoire of host-protective immune-response mechanisms, the outcome of which is largely determined by the balance of inflammatory (anti-tumor) and tolerogenic (pro-tumor) immune cell function in the tumor microenvironment (TME).1 By contributing to a tolerogenic TME, the regulatory T cell (Treg)...
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages
Highlights • We present a robust pipeline for scRNA-seq analysis by protein activity inference • Our pipeline identifies a C1Q+TREM2+APOE+ macrophage population enriched in ccRCC • Protein activity signature of these cells is prognostic of post-surgical recurrence • C1Q+ Macrophage association with recurrence is validated by immunohistochemistry Summary Clear cell renal carcinoma (ccRCC) is a heterogeneous disease with a variable post-surgical course.
Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway
AbstractPurpose: Agonist antibodies targeting the T-cell costimulatory receptor 4-1BB (CD137) are among the most effective immunotherapeutic agents across preclinical cancer models. In the clinic, however, development of these agents has been hampered by dose-limiting liver toxicity.
Despite KLRG1 expression, highly cytotoxic ThEO/TcEO polarized T cells efficiently establish immunologic memory
Targeting immune inhibitory (CTLA-4, PD-1) or stimulatory (OX-40, 4-1BB) co-receptors has proven to be a potent anti-cancer therapeutic strategy, eliciting robust anti-tumor T cell responses and yielding compelling pre-clinical and clinical data in a variety of cancers. We have previously shown in pre-clinical models that 4-1BB agonist antibodies engender strong anti-tumor T cell responses capable of driving regression of established tumors and durable tumor-free survival.
Mechanisms underlying 4-1BB agonist antibody mediated hepatotoxicity
Agonist antibodies against the T cell costimulatory receptor 4-1BB have proven extraordinarily efficacious in the treatment of a multitude of pre-clinical murine tumors both in mono- and combination therapy settings. Although administration of α4-1BB in Phase I and II clinical trials has led to disease stabilization and partial remission in some cases of melanoma; high grade, dose limiting liver inflammation has slowed the progress of these agents toward FDA approval.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Casey
Contact Casey, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack